Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

Chugai Pharmaceutical Co. Ltd. Stock , CHGCF

7,105.00 JPY +159.00 +2.29%
01:30:00 AM TOKIO
Plus500. 82% of retail CFD accounts lose money
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Chugai Pharmaceutical Stock Snapshot

72.38 B
Market Cap in USD
1.65 B
Number of Shares
1.65 B
Total Number of Shares
80.00
Dividend in JPY
1.50
Dividend Yield
27.00
P/E Ratio
37.20
Free Float in %
197.83
EPS in JPY
988.01
Book Value per Share in JPY
249.97
Cash Flow per Share in JPY
Start Trading Futures

Chugai Pharmaceutical Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

Chugai Pharmaceutical Estimates* in JPY

  2024 2025 2026 2027 2028
Revenue 1,152,366 1,167,341 1,216,389 1,330,769 1,509,508
Dividend 89.08 97.42 104.50 104.67 115.00
Dividend Yield (in %) 1.28 % 1.40 % 1.50 % 1.51 % 1.66 %
EPS 233.50 239.76 268.98 293.26 355.46
P/E Ratio 29.75 28.97 25.82 23.69 19.54
EBIT 529,450 536,597 580,281 632,596 723,300
EBITDA 567,847 575,451 609,785 645,513 755,100
Net Profit 384,105 394,510 429,917 514,875 604,300
Net Profit Adjusted 392,393 408,967 457,280 557,000 647,250
Pre-Tax Profit 536,073 541,595 589,003 656,967 743,750
Pre-Tax Profit Reported 542,322 564,471 604,543 667,200 743,750
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 236.35 244.25 270.09 321.38 375.25
Gross Income 822,455 835,317 883,400 1,011,000 1,150,900
Cash Flow from Investing -62,596 -62,067 -63,500 -61,000 -64,800
Cash Flow from Operations 405,337 422,236 438,275 481,548 514,413
Cash Flow from Financing -140,928 -157,782 -167,721 -171,739 -188,011
Cash Flow per Share 259.31 248.59 281.38 325.82 365.68
Free Cash Flow 343,690 352,604 376,110 413,522 449,613
Free Cash Flow per Share 149.50 177.30 189.20 222.20 226.30
Book Value per Share 1,132.18 1,269.09 1,423.25 1,600.66 1,903.08
Net Debt -779,436 -966,148 -1,174,823 -1,354,600 -1,555,700
Research & Development Exp. 177,082 180,960 187,620 202,867 221,000
Capital Expenditure 66,817 67,317 66,650 61,633 67,450
Selling, General & Admin. Exp. 176,380 179,040 184,180 223,000 236,850
Shareholder’s Equity 1,871,516 2,107,754 2,372,013 2,633,697 3,131,244
Total Assets 2,175,293 2,437,314 2,718,007 3,058,201 3,454,852
  Previous Quarter
ending 09/30/24 		Current Quarter
ending 12/31/24 		Next Quarter
ending 03/31/25 		Current Year
ending 12/31/24 		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts - 5 1 14 14
Average Estimate - 58.667 JPY 49.500 JPY 233.502 JPY 239.760 JPY
Year Ago - 55.434 JPY 45.219 JPY 197.830 JPY -
Publish Date - 1/30/2025 4/24/2025 - -
Revenue Estimates
No. of Analysts - 7 1 14 14
Average Estimate - 290,985 JPY 254,000 JPY 1,152,366 JPY 1,167,341 JPY
Year Ago - 273,812 JPY 236,949 JPY 1,111,367 JPY -
Publish Date - 1/30/2025 4/24/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. JPY

2023 2022 2021 2020 2019 2018 2017
Sales 1,111,367.00 1,259,946.00 999,758.00 786,945.00 686,184.00 579,787.00 534,199.00
Change of sales in % -11.79 26.03 27.04 14.68 18.35 8.53 8.63
Gross profit on sales 693,009.00 783,062.00 660,268.00 511,775.00 419,922.00 316,025.00 279,574.00
Gross profit on sales change in % -11.50 18.60 29.02 21.87 32.88 13.04 14.79
Operating income 415,665.00 533,942.00 433,738.00 306,882.00 214,513.00 129,225.00 102,973.00
Operating income change in % -22.15 23.10 41.34 43.06 66.00 25.49 29.82
Income before tax 443,821.00 531,166.00 419,385.00 298,188.00 207,893.00 121,449.00 97,031.00
Income before tax change in % -16.44 26.65 40.64 43.43 71.18 25.17 30.33
Income after tax 325,472.00 374,429.00 302,995.00 214,733.00 157,560.00 92,488.00 72,714.00
Income after tax change in % -13.08 23.58 41.10 36.29 70.36 27.19 35.68

Balance Sheet in Mio. JPY

2023 2022 2021 2020 2019 2018 2017
Total liabilities 306,966.00 445,371.00 350,677.00 255,494.00 204,929.00 163,020.00 159,576.00
Long-term liabilities per share 11.40 13.16 14.14 11.82 15.62 16.94 22.36
Equity 1,625,580.00 1,424,387.00 1,188,017.00 980,003.00 853,985.00 756,529.00 692,897.00
Equity change in % 14.12 19.90 21.23 14.76 12.98 9.24 7.19
Balance sheet total 1,932,546.00 1,869,758.00 1,538,694.00 1,235,497.00 1,058,914.00 919,549.00 852,473.00
Balance sheet total change in % 3.36 21.52 24.54 16.68 15.16 7.87 5.73

Key Data in JPY

2023 2022 2021 2020 2019 2018 2017
Sales per share 675.40 765.77 607.67 478.36 417.26 352.72 325.28
P/E ratio (year end quote, basic EPS) 27.00 14.80 20.27 42.12 35.02 37.73 43.37
P/E ratio (year end quote, diluted EPS) 27.01 14.80 20.28 42.16 35.07 37.80 43.44
P/E ratio (year end quote) 27.00 14.80 20.27 42.12 35.02 37.73 43.37
Dividend yield in % 1.50 2.32 2.03 1.00 1.39 1.35 1.07
Equity ratio in % 84.12 76.18 77.21 79.32 80.65 82.27 81.28
Debt ratio in % 15.88 23.82 22.79 20.68 19.35 17.73 18.72

Chugai Pharmaceutical Dividend Calendar

Date Name Dividend *yield Currency
2023 Chugai Pharmaceutical Co. Ltd. 80.00 1.50 JPY
2022 Chugai Pharmaceutical Co. Ltd. 78.00 2.32 JPY
2021 Chugai Pharmaceutical Co. Ltd. 76.00 2.03 JPY
2020 Chugai Pharmaceutical Co. Ltd. 55.00 1.00 JPY
2019 Chugai Pharmaceutical Co. Ltd. 46.67 1.39 JPY
2018 Chugai Pharmaceutical Co. Ltd. 28.67 1.35 JPY
2017 Chugai Pharmaceutical Co. Ltd. 20.67 1.07 JPY
2016 Chugai Pharmaceutical Co. Ltd. 17.33 1.55 JPY
2015 Chugai Pharmaceutical Co. Ltd. 19.33 1.37 JPY
2014 Chugai Pharmaceutical Co. Ltd. 16.00 1.62 JPY
2013 Chugai Pharmaceutical Co. Ltd. 15.00 1.94 JPY
2012 Chugai Pharmaceutical Co. Ltd. 13.33 2.42 JPY
2011 Chugai Pharmaceutical Co. Ltd. 13.33 3.15 JPY
2010 Chugai Pharmaceutical Co. Ltd. 13.33 2.68 JPY
2009 Chugai Pharmaceutical Co. Ltd. 40.00 2.30 JPY
*Yield of the Respective Date

Chugai Pharmaceutical Calendar

Event Estimate Info Date
Earnings Report 58.667 JPY Q4 2024 Earnings Release 01/30/2025
Earnings Report 49.500 JPY Q1 2025 Earnings Release 04/24/2025
Earnings Report - Q2 2025 Earnings Release 07/24/2025
Earnings Report - Q3 2025 Earnings Release 10/24/2025
Earnings Report - Q4 2025 Earnings Release 01/29/2026
Earnings Report - Q1 2026 Earnings Release 04/23/2026
Earnings Report - Q2 2026 Earnings Release 07/23/2026
Earnings Report - Q3 2026 Earnings Release 10/22/2026

Chugai Pharmaceutical Past Events

Event Actual EPS Info Date
Earnings Report 66.550 JPY Q3 2024 Earnings Release 10/25/2024
Earnings Report 67.980 JPY Q2 2024 Earnings Release 07/25/2024
Earnings Report 45.220 JPY Q1 2024 Earnings Release 04/24/2024
Annual General Meeting - Annual General Meeting 03/28/2024
Earnings Report 55.430 JPY Q4 2023 Earnings Release 02/01/2024
Earnings Report 47.150 JPY Q3 2023 Earnings Release 10/24/2023
Earnings Report 50.570 JPY Q2 2023 Earnings Release 07/27/2023
Earnings Report 44.680 JPY Q1 2023 Earnings Release 04/27/2023
Annual General Meeting - Annual General Meeting 03/30/2023
Earnings Report 62.300 JPY Q4 2022 Earnings Release 02/02/2023
Earnings Report 41.210 JPY Q3 2022 Earnings Release 10/24/2022
Earnings Report 44.000 JPY Q2 2022 Earnings Release 07/21/2022
Earnings Report 80.140 JPY Q1 2022 Earnings Release 04/25/2022
Annual General Meeting - Annual General Meeting 03/29/2022
Earnings Report 60.110 JPY Q4 2021 Earnings Release 02/03/2022

Chugai Pharmaceutical Profile

Chugai Pharmaceutical Co. , Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan. .

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Chugai Pharmaceutical Shareholder

Owner in %
Roche Holding AG 59.89
Freefloat 37.20
Chugai Pharmaceutical Co., Ltd. 2.00
Nomura Asset NEXT FUNDS NIKKEI 225 ETF (1321) 1.58
Nomura Asset NEXT FUNDS TOPIX ETF (1306) 1.09
Vanguard Health Care Fund 1.05
Nikko Exchange Traded Index Fund 225 0.77
Daiwa Asset iFreeETF NIKKEI 225 (Yearly Dividend Type) (1320) 0.72
Sumitomo Life Insurance Co. 0.54
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Chugai Pharmaceutical Management

Name Job
Mamoru Togashi Auditor
Atsushi Sato Auditor
Iwaaki Taniguchi Chief Financial Officer, Director & Executive VP
William N. Anderson Director
James H. Sabry Director
Christoph Franz Director
Minoru Watanabe Executive Officer
Toshihiko Komori Executive Officer
Shinji Hidaka Executive Officer & General Manager-Sales
Yoshiyuki Yano Executive Officer & Manager-Personnel
Junichi Nezu Executive Officer, GM-Research & Development
Yoko Kitagawa Group Manager-Finance & Accounting
Shinya Unno Head-Personnel, Legal & General Affairs
Yoshiaki Ohhashi Head-Quality & Regulatory Compliance Unit
Mariko Momoi Independent Outside Director
Yoichiro Ichimaru Independent Outside Director
Masayuki Oku Independent Outside Director
Osamu Okuda President, CEO & Representative Director
Yasushi Ito Senior Executive Officer
Keiji Kono Senior Executive Officer & Head-External Affairs
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Ebihara Senior Executive Officer & Manager-Legal Affairs
Motoo Ueno Vice Chairman & Head-Audit